In this week's column we will address a vexing cause of death and recommend ways for individuals to assess their risks and that of their immediate family members, and take steps to mitigate those risks.
Sudden death is a worrisome event that leaves families devasted and confused, especially when this occurs in otherwise healthy young individuals. While many causes of sudden death are yet to be properly understood, common causes are often cardiovascular in origin and measures exist that can be taken to identify individuals at increased risk and steps taken to reduce such risks for these individuals.
What is sudden death
Sudden death syndrome (SDS) is a compound term that encompasses a mixed group of heart-related syndromes that may cause sudden cardiac arrest, and likely death, unless prompt resuscitation is initiated. Cardiac arrest is not the same thing as a heart attack, as is often mistakenly assumed in the public. A heart attack, however, may lead to sudden cardiac arrest as a pathway to death unless properly treated in a timely manner. Many causes of sudden death result from structural abnormalities in the heart or problems with the electrical channels and conduction systems in the heart.
Heart function depends on both electrical and mechanical function, just like a motor vehicle. The electrical system is composed of various electrical channels and fibres that propagate electrical current to activate the muscles of the heart. This leads to initiation of the mechanical action that generates the heart pump and expels blood from the heart chambers to go to the vital organs. Any anomaly in the formation or performance of the electrical channels or structure (mechanical) may predispose individuals to cardiac arrest and sudden death. Some of these anomalies are well recognised and may be genetic and, in those cases, tend to run in families with clusters of family members being at risk or succumbing to sudden death episodes resulting from cardiac arrest.
Many individuals are unaware of their risks until a cardiac arrest occurs. Often, these are individuals who appear healthy and vibrant, therefore, cardiac arrest and sudden death are often traumatic to families and friends. Many cases of sudden death syndrome are not adequately diagnosed and may be mischaracterised as heart attack. Sudden death syndrome is more common in young and middle-aged individuals. When unexpected sudden death occurs in otherwise healthy and asymptomatic young and middle-aged individuals, it is referred to as sudden adult death syndrome. This syndrome occurs in all ethnic groups and populations but has been found to be particularly more common among Southeast Asians and other Asian communities.
In children, sudden infant death syndrome is well known. Electrical channel abnormalities and structural heart disease may be identified by standard cardiovascular tests. A common cause of sudden death from electrical channel abnormalities includes a pattern of electrocardiographic abnormalities recognised as Brugada syndrome, named after the Brugada brothers who first reported these anomalies in the medical literature. Another possible cause of dangerous electrical conduction abnormality is the long QT syndrome which may be identified by electrocardiogram or 24-hour Holter monitoring. Estimates from population studies suggest that five in 10,000 individuals have Brugada syndrome. It is also estimated that about one in 7,000 people may have long QT syndrome. Structural problems with the heart can often be recognised during echocardiograms in competent hands. Because these findings may be subtle, they can sometimes be missed or misdiagnosed by inexperienced operators and thus, opportunities for intervention missed.
Are you at risk?
Individuals at risk for sudden death syndrome may or may not have premonitory symptoms before a cardiac arrest or sudden death episode occurs. Except for those with prior heart attacks or other underlying heart disease, these individuals appear perfectly healthy and vibrant with no visible signs and symptoms prior to their first cardiac arrest or sudden death. However, there are certain risk factors that increase the likelihood of an individual having some of the conditions linked to sudden death syndrome. Researchers have identified some specific genetic profiles that are associated with increased risk of sudden death in individuals and their first-order relatives. Males are more likely than females to have cardiac arrest and sudden death and, as previously indicated, individuals with Asian heritage are at a higher risk when compared to the general population. Those persons with a family history of cardiac arrest or sudden death are at a higher risk of having cardiac arrest or sudden death and so, would benefit from a cardiac evaluation to assess their risks and make recommendations for mitigating those risks. Individuals with underlying heart disease and/or arrhythmias are vulnerable to cardiac arrest and sudden death episodes and so would warrant close attention.
One very important cause of cardiac arrest and sudden death is referred to as hypertrophic cardiomyopathy, a condition that results in severe thickening of the heart muscles and alteration in the electrical conduction system of the heart. This is a condition that has been linked to specific genetic mutations and has been responsible for a significant number of sudden death episodes in young and middle-aged individuals. Sudden death in young athletes is frequently linked to hypertrophic cardiomyopathy. Certain clinical parameters in individuals with hypertrophic cardiomyopathy may help in predicting risk for future cardiac arrest or sudden death. Individuals with hypertrophic cardiomyopathy are encouraged to seek appropriate cardiology evaluation.
A key cause of sudden death is dilated cardiomyopathy in which the heart chambers are enlarged and the pumping function is reduced. Dilated cardiomyopathy may be due to severe coronary artery disease (ischemic) or may be unrelated to coronary artery disease (non-ischemic). Important non ischemic causes of dilated cardiomyopathy include long standing, poorly treated hypertension, valve disease and prior viral myocarditis. Some individuals with dilated cardiomyopathy may respond well to a cocktail of medications that improve the remodeling of the heart muscles and ejection fraction. Individuals who respond well to medical therapy with improvement in ejection fraction also see a reduction in their risk for cardiac arrest and sudden death. In those individuals with poor response to medical therapy, sudden death risk remains high.
Arrhythmogenic right ventricular dysplasia (ARVD) is an uncommon but important type of cardiomyopathy that is associated with sudden death. It occurs if the muscle tissue in the right ventricle dies and is replaced with scar tissue. This causes a disruption in the heart's electrical activity, resulting in arrhythmias. Individuals with ARVD may have recurrent episodes of palpitations and fainting after physical activity.
What are the symptoms
Unfortunately, for many individuals, there is no warning sign or symptom. In many cases, the first symptom or sign of sudden death syndrome may be sudden and unexpected death.
However, sudden death syndrome can cause the following red-flag symptoms:
chest pain or shortness of breath, especially during exercise
A feeling of fluttering in the chest or palpitations at rest or with exercise
episodes of loss of consciousness or recurrent dizzy spells
unexplained fainting, especially during or immediately after exercise
If you or someone you know experience any of these symptoms, we would encourage you to seek immediate medical attention.
How is SDS diagnosed?
SDS is only diagnosed when you go into sudden cardiac arrest. However, the various abnormalities and syndromes that lead to sudden death may be identified by well-trained cardiologists using simple, non-invasive cardiac diagnostic techniques. An ECG, for example, can identify many of the syndromes that can cause sudden death.
Appropriately trained and experienced cardiologists can look at the ECG strip and identify potential problems such as underlying arrhythmias, Brugada syndrome, long QT syndrome, short QT syndrome and other conduction abnormalities. When an ECG fails to reveal a problem in patients with suggestive symptoms, an ambulatory electrocardiogram (Holter) will be performed over a prolonged period (24-72 hours), and this may yield valuable information. In some instances, it may be necessary to insert an implantable loop recorder under the subcutaneous tissue in the chest for several weeks to months to record and analyse electrical activity.
An echocardiogram, which is an ultrasound scan of the heart, is a valuable technique in identifying possible problems, especially when properly done and expertly interpreted. With this test, the cardiologist can see your heart beating in real time and can determine if there are structural or performance problems with the heart muscles, cardiac chambers, or valves all of which may factor into the risk for sudden death.
ARVD is diagnosed based on your medical history, physical exam, and tests (echocardiogram, Holter monitor, electrophysiologic testing, cardiac MRI, and/or cardiac CT scan).
Anyone experiencing symptoms associated with SDS may receive one of these tests. Similarly, people with a medical or family history that suggests SDS may want to be evaluated to determine if any of these tests would be necessary for them.
Identifying the risk early can help you learn ways to prevent possible cardiac arrest.
Dr Ernest Madu, MD, FACC and Dr Paul Edwards, MD, FACC are consultant cardiologists at Heart Institute of the Caribbean (HIC) and HIC Heart Hospital
Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at https://bit.ly/epaper-login
Read the original here:
Are you at risk for sudden death, and can it be prevented? - Jamaica Observer
- Managing Right Ventricular Failure in PAH: An Algorithmic Approach | Advances in ... - April 13th, 2018 [April 13th, 2018]
- What Is the Ejection Fraction? - Verywell Health - May 12th, 2018 [May 12th, 2018]
- Ventricular septal defect - Wikipedia - June 21st, 2018 [June 21st, 2018]
- Heart Failure Medication: Beta-Blockers, Alpha Activity ... - July 7th, 2018 [July 7th, 2018]
- Acute Management of Pulmonary Embolism - American College ... - July 17th, 2018 [July 17th, 2018]
- Ventricular Remodeling | Profiles RNS - July 24th, 2018 [July 24th, 2018]
- Left ventricular hypertrophy - Wikipedia - August 20th, 2018 [August 20th, 2018]
- Ventricular Remodeling Surgery (SVR) - September 24th, 2018 [September 24th, 2018]
- Left Ventricular Remodeling in Heart Failure | JACC ... - November 25th, 2018 [November 25th, 2018]
- Ventricular dysfunction in heart failure - Britannica.com - December 25th, 2018 [December 25th, 2018]
- TIMI Study Group - LEADERSHIP - January 31st, 2019 [January 31st, 2019]
- Ventricular Remodeling Procedure | Main Line Health ... - February 24th, 2019 [February 24th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS) - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Reviewing Aeterna Zentaris Inc. (AEZS)'s and BioLineRx Ltd. (NASDAQ:BLRX)'s results - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Karuna Therapeutics Inc. (KRTX) and BioLineRx Ltd. (NASDAQ:BLRX) Comparing side by side - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) - The EN Herald - September 18th, 2019 [September 18th, 2019]
- Cardiac Dimensions touts Carillon TMVR study - Mass Device - September 18th, 2019 [September 18th, 2019]
- New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF - TCTMD - September 18th, 2019 [September 18th, 2019]
- Cardiac Restoration Systems Market Will Make a Huge Impact in Near Future - Wolf Mirror - September 18th, 2019 [September 18th, 2019]
- Reduce Fmr Study Shows Cardiac Dimensions' Carillon System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure - TCTMD - September 18th, 2019 [September 18th, 2019]
- Heart Failure Society of America 2019: Virtual Visits, Spironolactone Issues, and Reasons to Worry - DocWire News - September 18th, 2019 [September 18th, 2019]
- LV Reverse Remodeling Not Improved by SGLT-2 Inhibitor - DocWire News - September 18th, 2019 [September 18th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Soligenix Inc. (NASDAQ:SNGX) - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts - The MAK Daily - September 22nd, 2019 [September 22nd, 2019]
- Reviewing BioLineRx Ltd. (BLRX)'s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)'s results - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Comparison of Protalix BioTherapeutics Inc. (PLX) and BioLineRx Ltd. (NASDAQ:BLRX) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for... - November 7th, 2019 [November 7th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) - The Broch Herald - December 3rd, 2019 [December 3rd, 2019]
- Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT - Yahoo Finance - December 3rd, 2019 [December 3rd, 2019]
- Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 - 2028 - The Market Expedition - December 3rd, 2019 [December 3rd, 2019]
- Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD - Dove Medical Press - December 3rd, 2019 [December 3rd, 2019]
- 3 Stocks to Buy Ahead of the Next Market Crash - The Motley Fool - December 3rd, 2019 [December 3rd, 2019]
- Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival - TCTMD - December 3rd, 2019 [December 3rd, 2019]
- Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy - AJMC.com Managed Markets Network - December 4th, 2019 [December 4th, 2019]
- BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System - Yahoo Finance - December 4th, 2019 [December 4th, 2019]
- Cardiac Restoration Systems Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2055 2017 2025 - Weekly News Times - December 13th, 2019 [December 13th, 2019]
- The Outer Line: The impact of endurance training on the cardiac health of women - VeloNews - December 13th, 2019 [December 13th, 2019]
- Contrasting of Insmed Incorporated (INSM) and BioLineRx Ltd. (NASDAQ:BLRX) - The CoinGlobalist - December 16th, 2019 [December 16th, 2019]
- CARDIAC RESTORATION SYSTEMS MARKET ANALYSIS TRENDS, GROWTH OPPORTUNITIES, SIZE, TYPE, DYNAMIC DEMAND AND DRIVES WITH FORECASTS TO 2028 - Voice of... - January 13th, 2020 [January 13th, 2020]
- Early Expressed Circulating Long Noncoding RNA CHAST is Associated with Cardiac Contractile Function in Patients with Acute Myocardial Infarction -... - January 13th, 2020 [January 13th, 2020]
- Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone - DocWire News - January 23rd, 2020 [January 23rd, 2020]
- Increased Long-Term Risk for Venous Thromboembolism After Heart Failure - The Cardiology Advisor - January 23rd, 2020 [January 23rd, 2020]
- Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity - Science Advances - February 1st, 2020 [February 1st, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - The Cardiology Advisor - February 1st, 2020 [February 1st, 2020]
- New Data Confirms Cardiac Dimensions' Carillon System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation -... - February 26th, 2020 [February 26th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Yahoo Finance - March 5th, 2020 [March 5th, 2020]
- Relationship between histopathological features of aspirated thrombi and long-term left ventricular function in patients with ST-segment elevation... - March 15th, 2020 [March 15th, 2020]
- FierceMedTech Names BioVentrix as One of Its "Fierce 15" Companies of 2019 - Yahoo Finance - March 15th, 2020 [March 15th, 2020]
- Causes and Prevention of Ventricular Remodeling After MI ... - March 16th, 2020 [March 16th, 2020]
- Left Ventricular Remodelling - ECR Journal - April 23rd, 2020 [April 23rd, 2020]
- Cardiac Restoration Systems Market to Make Great Impact in Near Future by 2026 - The Canton Independent Sentinel - June 12th, 2020 [June 12th, 2020]
- Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes - The Cardiology Advisor - June 12th, 2020 [June 12th, 2020]
- Chronic PDE5i Treatment Found to Improve Cardiac Remodeling in Men, but Not Women, With Diabetic Cardiomyopathy - Endocrinology Advisor - June 12th, 2020 [June 12th, 2020]
- Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020... - June 23rd, 2020 [June 23rd, 2020]
- American Heart Association and Barth Syndrome Foundation Partner to Address Rare Disease - PR Web - August 29th, 2020 [August 29th, 2020]
- The Association of Cardio-Ankle Vascular Index (CAVI) with Biatrial Remodeling in Atrial Fibrillation - DocWire News - September 3rd, 2020 [September 3rd, 2020]
- Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral... - September 3rd, 2020 [September 3rd, 2020]
- Sep 4 2020 This Week in Cardiology - Medscape - September 5th, 2020 [September 5th, 2020]
- Emerging treatment helps reverse heart failure in some patients - Science Codex - October 27th, 2020 [October 27th, 2020]
- GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial - PRNewswire - October 27th, 2020 [October 27th, 2020]
- North America to Outshine the Global Slowdown in Cardiac Restoration Systems market between 2020 and 2030 - The Think Curiouser - November 12th, 2020 [November 12th, 2020]
- Age-Related Development of Cardiac Remodeling and Dysfunction in Young Black and White Adults: the Coronary Artery Risk Development in Young Adults... - November 25th, 2020 [November 25th, 2020]
- Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin - Science Advances - January 13th, 2021 [January 13th, 2021]
- Longer Survival Seen in Heart Failure Stabilized Via Cardiac Resynchronization Therapy - The Cardiology Advisor - April 13th, 2021 [April 13th, 2021]
- Cardiac Dimensions Welcomes Robert White to its Board of Directors - PRNewswire - April 13th, 2021 [April 13th, 2021]
- [Full text] SIRT1 is Required for Exercise-Induced Beneficial Effects on Myocardia | JIR - Dove Medical Press - April 13th, 2021 [April 13th, 2021]
- Role of Pyroptosis in Diabetes and Its Therapeutic Implications | JIR - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Does a plant-based diet improve cardiac function? Here's the answer - Hindustan Times - June 21st, 2021 [June 21st, 2021]
- Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI - AJMC.com Managed Markets Network - November 5th, 2021 [November 5th, 2021]
- Higher BP, LV Changes Seen in Children Conceived by ART - Medscape - November 5th, 2021 [November 5th, 2021]
- Regional Heterogeneity in Determinants of Atrial Matrix Remodeling and Association with Atrial Fibrillation Vulnerability Post-Myocardial Infarction -... - January 26th, 2022 [January 26th, 2022]
- 4 promising heart failure therapies interventional cardiologists should keep an eye on - Cardiovascular Business - May 7th, 2022 [May 7th, 2022]
- LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - Yahoo Finance - May 7th, 2022 [May 7th, 2022]
- Ventricular structure and function in hypertensive patients | IJGM - Dove Medical Press - May 7th, 2022 [May 7th, 2022]
- Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction:... - May 7th, 2022 [May 7th, 2022]
- Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study - Business Wire - September 12th, 2022 [September 12th, 2022]